Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Oct 2;10(10):95.
doi: 10.1038/s41408-020-00363-6.

Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma

Marcella A Tschautscher  1 , Dragan Jevremovic  2 , Francis K Buadi  1 , Martha Q Lacy  1 , Morie A Gertz  1 , Angela Dispenzieri  1 , Prashant Kapoor  1 , David Dingli  1 , Lisa Hwa  1 , Amie Fonder  1 , Miriam Hobbs  1 , Suzanne Hayman  1 , John Lust  1 , Stephen J Russell  3 , Nelson Leung  4 , Ronald S Go  1 , Yi Lin  1 , Wilson Gonsalves  1 , Taxiarchis Kourelis  1 , Rahma Warsame  1 , Robert A Kyle  1 , S Vincent Rajkumar  1 , Shaji Kumar  5
Affiliations
Editorial

Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma

Marcella A Tschautscher et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Post-transplant bone marrow biopsy plasma cell percentage with corresponding post-transplant immunofixation status among patients proceeding to ASCT with bone marrow plasma cells <5%, but IFE positivity.
All patients represented in scatter plot met inclusion parameters including pre-transplant BMPC < 5% and pre-transplant serum or urine IFE positivity (n = 277). Among patients with post-transplant IFE positivity, 14 had BMPC > 5%. Among those with post-transplant IFE negativity, 2 had BMPC > 5%.
See this image and copyright information in PMC

References

    1. Kumar S, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. The Lancet Oncology. 2016;17:e328–e346. doi: 10.1016/S1470-2045(16)30206-6. - DOI - PubMed
    1. Chee CE, et al. The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma. Blood. 2009;114:2617–2618. doi: 10.1182/blood-2009-01-198788. - DOI - PMC - PubMed
    1. van de Velde HJK, et al. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica. 2007;92:1399–1406. doi: 10.3324/haematol.11534. - DOI - PubMed
    1. Paiva B, van Dongen JJM, Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood. 2015;125:3059–3068. doi: 10.1182/blood-2014-11-568907. - DOI - PMC - PubMed
    1. Paiva, B. et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. 29, J.Clin. Oncol. 1627–1633 (2011) - PubMed

Publication types